Is Pycnogenol Exercise Performance Randomized Trial safe?

Updated October 2026

Quick Answer

Pycnogenol Exercise Performance Randomized Trial has evidence relevant to safety, limits, and clinician-discussion contexts, but conclusions should stay close to the cited sources. One representative finding is: Objective To describe the distribution and day-to-day variability of EuroQol Visual Analogue Scale (EQ-VAS) values and to estimate a minimal important difference (MID) in adults with post-COVID-19 condition (PCC).

Key Takeaways

  • 01Objective To describe the distribution and day-to-day variability of EuroQol Visual Analogue Scale (EQ-VAS) values and to estimate a minimal important difference (MID) in adults with post-COVID-19 condition (PCC). [Kopp J (2026)]
  • 02Design Secondary analysis of pooled EQ-VAS data from both arms of a 12-week randomised, placebo-controlled trial (PYCNOVID) of Pycnogenol (200 mg/day) versus placebo in adults with PCC. [Kopp J (2026)]
  • 03Figure 1 Thus, in the present review we aimed to summarize the preclinical and clinical evidence of selected nutraceuticals, focusing on biotin, flavonoids especially luteolin, folic acid, Huperzine A, Lion’s mane, olive oil polyphenols (oleuropein and hydroxytyrosol [HT]), and palmitoylethanolamide (PEA). [Venetsanaki Vasiliki (2026)]
  • 04The present narrative review highlights current mechanistic insights, as well as evidence from experimental and clinical studies regarding their potential roles in supporting cognitive function, modulating neuroinflammation, and mitigating neurodegenerative processes. [Venetsanaki Vasiliki (2026)]
The current Migaku evidence database contains 2 reusable source documents for Pycnogenol Exercise Performance Randomized Trial. This answer focuses on safety, limits, and clinician-discussion contexts. - Objective To describe the distribution and day-to-day variability of EuroQol Visual Analogue Scale (EQ-VAS) values and to estimate a minimal important difference (MID) in adults with post-COVID-19 condition (PCC). [Kopp J (2026); evidence level 2] - Design Secondary analysis of pooled EQ-VAS data from both arms of a 12-week randomised, placebo-controlled trial (PYCNOVID) of Pycnogenol (200 mg/day) versus placebo in adults with PCC. [Kopp J (2026); evidence level 2] - Figure 1 Thus, in the present review we aimed to summarize the preclinical and clinical evidence of selected nutraceuticals, focusing on biotin, flavonoids especially luteolin, folic acid, Huperzine A, Lion’s mane, olive oil polyphenols (oleuropein and hydroxytyrosol [HT]), and palmitoylethanolamide (PEA). [Venetsanaki Vasiliki (2026); evidence level 3] - The present narrative review highlights current mechanistic insights, as well as evidence from experimental and clinical studies regarding their potential roles in supporting cognitive function, modulating neuroinflammation, and mitigating neurodegenerative processes. [Venetsanaki Vasiliki (2026); evidence level 3] - It should be noted that the present work consists of a review and not a dosing guideline. [Venetsanaki Vasiliki (2026); evidence level 3] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.

Sources

  1. Within-person variability and the minimal important difference of the EQ-VAS in adults with post-COVID-19 condition: a secondary analysis of data from a single-centre randomised controlled trial.
  2. Natural Molecules for Brain Health and Resilience